COMPARING THE EFFECT OF TWO MEDICATIONS DEXMEDETOMIDINE AND MAGNESIUM SULPHATE ON HOW QUICKY ATRACURIUM TAKES EFFECT,MEASURED USING A TRAIN OF FOUR NEUROMUSCULAR MONITOR

Comparing the Effect of Bolus Intravenous Dexmedetomidine Vs Magnesium Sulphate On Onset of Atracurium using a TOF Monitor-A Randomised Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080632

Enrollment

Registered

2025-02-14

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K35-K38- Diseases of appendix Health Condition 2: K20-K31- Diseases of esophagus, stomach and duodenum Health Condition 3: H65-H75- Diseases of middle ear and mastoid Health Condition 4: K00-K14- Diseases of oral cavity and salivary glands Health Condition 5: K80-K87- Disorders of gallbladder, biliary tract and pancreas Health Condition 6: K40-K46- Hernia Health Condition 7: 8- Other Procedures

Interventions

Intervention1: Dexmedetomidine Magnesium sulphate Atracurium TOF monitor: Dexmedetomidine/MagnesiumSulphate through intravenous route Dexmedetomidine 0.5mcg/kg i.v Magnesium sulphate 50mg/kg i.v Conne

Eligibility

Inclusion criteria

Inclusion criteria: a. ASA Grade I and Grade II patients b. Age 18 yrs-60yrs. c. Elective surgeries

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Time required for TOF value to change from 4 to 0Timepoint: Baseline After drug changes Pre intubation Post intubation	—

Secondary

Measure	Time frame
Time required for TOF value to change from 0 to 1Timepoint: 30 mins,45 mins,60 mins	—

Countries

India

Contacts

Public ContactDr.Harshanaa.G

Chettinad Academy of Research and Education

dranandmurugan@gmail.com9444486183

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026